A Phase 2 interventional study of Apremilast and Placebo in Palmoplantaris Pustulosis, sponsored by Amgen. Completed at 22 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2024-07-17.
Sponsored by Amgen · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing apremilast in Psoriasis — 5 open to participants now, 5 under way, none of them phase 3. apremilast · Psoriasis.
Among the 44 studies testing apremilast in Psoriasis, this one is the 24th largest by enrollment, is one of 6 that started in 2019, is one of 10 in phase 2, and was the 31st registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →5 of the 44 studies testing apremilast in Psoriasis are open now, in 3 countries. Recruiting first, the newest first:
Syeda Sana Zaman · Sites in Pakistan
Ages 18–60 · Healthy volunteers
University of Athens · Sites in Greece
Ages 18–80 · Healthy volunteers
Amgen
Ages 18–60 · Healthy volunteers
University of California, San Francisco · Sites in United States
Ages 18+
Zarmeen Khawar · Sites in Pakistan
Ages 18–65
By country, each count listing its studies:
apremilast: first FDA approval 2014 (OTEZLA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 6 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 90 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 103 across the 44 interventional studies. Of the 34 that completed or were terminated, 26 (76%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 44 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
61 studies in Psoriasis by Amgen: 1 open now, 1 under way, none of them phase 3. Of 60 finished, 35 (58%) have results posted.
Among the 61 studies in Psoriasis by Amgen, this one is the 38th largest by enrollment of the 49 interventional ones that give a count, is one of 7 that started in 2019, is one of 8 in phase 2, and was the 52nd registered.
Amgen’s Psoriasis studies by the year they started, since 2000.
1 of the studies testing apremilast in Psoriasis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07908641AmgenComparing the Extent to Which Apremilast is Made Available in the Body After Administration as an Extended-release or Immediate-release Formulation | 2027-01-10 |
Add it to your calendar (.ics) → With an account.
Among the 44 studies testing apremilast in Psoriasis, from their registry updates:
Among Amgen’s 61 in Psoriasis:
This tab as a report to print or save as PDF → With an account.
This study will evaluate whether apremilast is better than placebo (inactive substance in the same form as the drug) for the treatment in Japanese subjects with PPP. This study also will evaluate the safety and tolerability of apremilast in Japanese subjects with PPP.CC-10004-PPP-001 is a multicenter, randomized, double-blind, placebo-controlled, parallel group, Phase 2 study of apremilast in Japanese subjects with PPP and inadequate response to treatment with topical steroid and/or topical vitamin D3 derivative preparations.
The placebo-controlled period will be 16 weeks and patients will receive apremilast or placebo. After the 16-week placebo-controlled period, all subjects will receive apremilast for 16 weeks. All subjects will have their final study visit 4 weeks after stopping apremilast treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects must satisfy the following criteria to be enrolled in the study:
Exclusion Criteria:
The presence of any of the following will exclude a subject from enrollment:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received matched placebo as oral tablets twice daily (BID) for up to 16 weeks (Week 0 to Week 16). Participants who completed the placebo-controlled phase entered the active-treatment phase and received apremilast 30 mg as oral tablets BID for up to an additional 16 weeks (Week 16 to Week 32).
Drug: Apremilast · Drug: Placebo
Participants received apremilast 30 mg as oral tablets BID for up to 16 weeks (Week 0 to Week 16). Participants who completed the placebo-controlled phase entered the active-treatment phase and received apremilast 30 mg as oral tablets BID for up to an additional 16 weeks (Week 16 to Week 32).
Drug: Apremilast
Apremilast
Also known as: CC-10004
Placebo
Percentage of Participants Who Achieve a PPPASI-50 at Week 16
PPPASI-50 is defined as \>= 50 percent decrease in PPPASI total score from baseline. PPPASI is a disease-specific efficacy assessment tool to evaluated for 3 signs of the disease (erythema, pustules/vesicle and desquamation/scale) as sub-scores on palms or soles. The PPPASI total scores are calculated by sum of the sub-scores and range from 0 to 72 with a higher score indicating more severe disease.
Time frame: At Week 16
Percentage of Participants Who Achieve a PPPASI-50 at All Other Visits in Placebo-controlled Phase
PPPASI-50 is defined as \>= 50 percent decrease in PPPASI total score from baseline. PPPASI is a disease-specific efficacy assessment tool to evaluated for 3 signs of the disease (erythema, pustules/vesicle and desquamation/scale) as sub-scores on palms or soles. The PPPASI total scores are calculated by sum of the sub-scores and range from 0 to 72 with a higher score indicating more severe disease. Missing values at were imputed using non-responder imputation (NRI) as the primary method, by which a participant without sufficient data for the response determination was considered a non-responder.
Time frame: Weeks 2 to 14
Percentage of Participants Who Achieve a PPPASI-75 at Each Visit in Placebo-controlled Phase
PPPASI-75 is defined as \>=75 percent decrease in PPPASI total score from baseline. PPPASI is a disease-specific efficacy assessment tool to evaluated for 3 signs of the disease (erythema, pustules/vesicle and desquamation/scale) as sub-scores on palms or soles. The PPPASI total scores are calculated by sum of the sub-scores and range from 0 to 72 with a higher score indicating more severe disease. Missing values were imputed using NRI as the primary method, by which a participant without sufficient data for the response determination was considered a non-responder.
Time frame: Weeks 2 to 16
Area Under the Curve (AUC) of PPPASI Total Score From Baseline Through Week 16
The AUC for PPPASI total score from baseline through Week 16 is the sum of the AUCs in each time interval specified by the dates of the visits and is calculated based on the linear trapezoidal method. PPPASI is a disease-specific efficacy assessment tool to evaluate 3 signs of the disease (erythema, pustules/vesicle and desquamation/scale) as sub-scores on palms or soles. The PPPASI total scores are calculated by sum of the sub-scores and range from 0 to 72 with a higher score indicating more severe disease.
Time frame: Baseline to Week 16
Percent Change From Baseline in PPPASI Total Score by Visit in Placebo-controlled Phase .
PPPASI is a disease-specific efficacy assessment tool to evaluated for 3 signs of the disease (erythema, pustules/vesicle and desquamation/scale) as sub-scores on palms or soles. The PPPASI total scores are calculated by sum of the sub-scores and range from 0 to 72 with a higher score indicating more severe disease. A positive change from baseline indicates a worsening of symptoms.
Time frame: Baseline to Week 16
Change From Baseline in PPPASI Total Score at Week 16
PPPASI is a disease-specific efficacy assessment tool to evaluated for 3 signs of the disease (erythema, pustules/vesicle and desquamation/scale) as sub-scores on palms or soles. The PPPASI total scores are calculated by sum of the sub-scores and range from 0 to 72 with a higher score indicating more severe disease. Change from baseline based on a mixed-effects model for repeated measures with a positive change indicating a worsening of symptoms.
Time frame: Baseline and Week 16
AUC for PPSI Total Score From Baseline Through Week 16
The AUC for PPSI total score from baseline through Week 16 is the sum of the AUCs in each time interval specified by the dates of the visits and is calculated based on the linear trapezoidal method. PPSI is a disease-specific assessment tool for grading the severity of PPP lesions. Evaluation of skin lesion sites are assessed separately for erythema, pustules/vesicle and desquamation/scale, which are each rated on a scale of 0 to 4. The PPSI produces a total numeric score that ranges from 0 to 12. A higher score indicates more severe disease.
Time frame: Baseline to Week 16
Percent Change From Baseline in PPSI Total Score by Visit in Placebo-controlled Phase
PPSI is a disease-specific assessment tool for grading the severity of PPP lesions. Evaluation of skin lesion sites are assessed separately for erythema, pustules/vesicle and desquamation/scale, which are each rated on a scale of 0 to 4. The PPSI produces a total numeric score that ranges from 0 to 12. A higher score indicates more severe disease. A positive change from baseline indicates a worsening of symptoms.
Time frame: Baseline to Week 16
Change From Baseline in PPSI Total Score at Week 16
PPSI is a disease-specific assessment tool for grading the severity of PPP lesions. Evaluation of skin lesion sites are assessed separately for erythema, pustules/vesicle and desquamation/scale, which are each rated on a scale of 0 to 4. The PPSI produces a total numeric score that ranges from 0 to 12. A higher score indicates more severe disease. Change from baseline based on a mixed-effects model for repeated measures with a positive change indicating a worsening of symptoms.
Time frame: Baseline and Week 16
Percentage of Participants Achieving a PGA Score of Clear (0) or Minimal (1) by Visit in Placebo-controlled Phase
The PGA for palms and soles was used to determine the participants PPP lesions on palms and soles. Lesions on palms and soles were graded based on the following scales: 0 = Clear 1. = Almost clear/Minimal 2. = Mild 3. = Moderate 4. = Severe 5. = Very severe. The percentage of of participants with a post baseline score of 0 or 1 (responders) are reported. Missing values at were imputed using NRI as the primary method, by which a participant without sufficient data for the response determination was considered a non-responder.
Time frame: Weeks 2 to 16
Percentage of Participants Achieving a PGA Score of 0 or 1 With At Least a 2 Grade Improvement by Visit in Placebo-controlled Phase.
The PGA for palms and soles was used to determine the participants PPP lesions on palms and soles. Lesions on palms and soles were graded based on the following scales: 0 = Clear 1. = Almost clear/Minimal 2. = Mild 3. = Moderate 4. = Severe 5. = Very severe. The percentage of of participants with at least a 2 grade improvement from baseline (stringent responders) are reported. issing values at were imputed using NRI as the primary method, by which a participant without sufficient data for the response determination was considered a non-responder.
Time frame: Weeks 2 to 16
Change From Baseline in Participant VAS Assessment for PPP Symptoms
Participants assessed the degree of both pruritus itching and skin discomfort/pain as symptoms on hands and feet caused by PPP on a VAS. Each score ranged from 0 to 100. The left-hand boundary (0) on the VAS represents no itch/pain and the right-hand boundary (100) represents itch/pain as severe as can be imagined by participant.
Time frame: Baseline and Weeks 2,4,6,8,12,16
Japanese participants with palmoplantar pustulosis (PPP) were enrolled at 22 research centers in Japan from October 2019 to June 2021.
| Milestone | Placebo Then Apremilast 30mg BID | Apremilast 30 mg BID Then Apremilast 30 mg BID |
|---|---|---|
| Started | 44 | 46 |
| Completed | 41 | 46 |
| Not completed | 3 | 0 |
| Withdrew: Adverse event | 3 | 0 |
| Milestone | Placebo Then Apremilast 30mg BID | Apremilast 30 mg BID Then Apremilast 30 mg BID |
|---|---|---|
| Started | 41 | 46 |
| Completed | 40 | 44 |
| Not completed | 1 | 2 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Withdrew: Pregnancy | 0 | 1 |
| Withdrew: Physician decision | 0 | 1 |
PPPASI-50 is defined as \>= 50 percent decrease in PPPASI total score from baseline. PPPASI is a disease-specific efficacy assessment tool to evaluated for 3 signs of the disease (erythema, pustules/vesicle and desquamation/scale) as sub-scores on palms or soles. The PPPASI total scores are calculated by sum of the sub-scores and range from 0 to 72 with a higher score indicating more severe disease.
| Percentage of Partcipants | Placebo-controlled Phase - Placebo | Placebo-controlled Phase - Apremilast 30 mg BID |
|---|---|---|
| Percentage of Participants Who Achieve a PPPASI-50 at Week 16 | 40.9 | 78.3 |
PPPASI-50 is defined as \>= 50 percent decrease in PPPASI total score from baseline. PPPASI is a disease-specific efficacy assessment tool to evaluated for 3 signs of the disease (erythema, pustules/vesicle and desquamation/scale) as sub-scores on palms or soles. The PPPASI total scores are calculated by sum of the sub-scores and range from 0 to 72 with a higher score indicating more severe disease. Missing values at were imputed using non-responder imputation (NRI) as the primary method, by which a participant without sufficient data for the response determination was considered a non-responder.
| Percentage of Participants | Placebo-controlled Phase - Placebo | Placebo-controlled Phase - Apremilast 30 mg BID |
|---|---|---|
| Week 2 | 2.3 | 30.4 |
| Week 4 | 18.2 | 52.2 |
| Week 6 | 18.2 | 69.6 |
| Week 8 | 43.2 | 65.2 |
| Week 10 | 34.1 | 71.7 |
| Week 12 | 34.1 | 69.6 |
| Week 14 | 47.7 | 73.9 |
PPPASI-75 is defined as \>=75 percent decrease in PPPASI total score from baseline. PPPASI is a disease-specific efficacy assessment tool to evaluated for 3 signs of the disease (erythema, pustules/vesicle and desquamation/scale) as sub-scores on palms or soles. The PPPASI total scores are calculated by sum of the sub-scores and range from 0 to 72 with a higher score indicating more severe disease. Missing values were imputed using NRI as the primary method, by which a participant without sufficient data for the response determination was considered a non-responder.
| Percentage of Partcipants | Placebo-controlled Phase - Placebo | Placebo-controlled Phase - Apremilast 30 mg BID |
|---|---|---|
| Week 2 | 2.3 | 2.2 |
| Week 4 | 4.5 | 10.9 |
| Week 6 | 9.1 | 21.7 |
| Week 8 | 11.4 | 19.6 |
| Week 10 | 11.4 | 30.4 |
| Week 12 | 13.6 | 30.4 |
| Week 14 | 13.6 | 37.0 |
| Week 16 | 15.9 | 43.5 |
The AUC for PPPASI total score from baseline through Week 16 is the sum of the AUCs in each time interval specified by the dates of the visits and is calculated based on the linear trapezoidal method. PPPASI is a disease-specific efficacy assessment tool to evaluate 3 signs of the disease (erythema, pustules/vesicle and desquamation/scale) as sub-scores on palms or soles. The PPPASI total scores are calculated by sum of the sub-scores and range from 0 to 72 with a higher score indicating more severe disease.
| Scores * Day | Placebo-controlled Phase - Placebo | Placebo-controlled Phase - Apremilast 30 mg BID |
|---|---|---|
| Area Under the Curve (AUC) of PPPASI Total Score From Baseline Through Week 16 | 1911.74 (1707.92 to 2115.57) | 1337.49 (1134.52 to 1540.47) |
PPPASI is a disease-specific efficacy assessment tool to evaluated for 3 signs of the disease (erythema, pustules/vesicle and desquamation/scale) as sub-scores on palms or soles. The PPPASI total scores are calculated by sum of the sub-scores and range from 0 to 72 with a higher score indicating more severe disease. A positive change from baseline indicates a worsening of symptoms.
| Percent Change | Placebo-controlled Phase - Placebo | Placebo-controlled Phase - Apremilast 30 mg BID |
|---|---|---|
| Week 2 | -11.09 ± 22.102 | -36.62 ± 22.816 |
| Week 4 | -23.82 ± 28.307 | -48.96 ± 21.973 |
| Week 6 | -30.15 ± 24.826 | -55.06 ± 23.164 |
| Week 8 | -42.41 ± 27.115 | -57.11 ± 22.710 |
| Week 10 | -36.52 ± 32.999 | -60.85 ± 21.792 |
| Week 12 | -42.30 ± 26.802 | -61.22 ± 22.787 |
| Week 14 | -45.00 ± 30.915 | -63.78 ± 23.952 |
| Week 16 | -42.35 ± 32.671 | -64.33 ± 24.345 |
PPPASI is a disease-specific efficacy assessment tool to evaluated for 3 signs of the disease (erythema, pustules/vesicle and desquamation/scale) as sub-scores on palms or soles. The PPPASI total scores are calculated by sum of the sub-scores and range from 0 to 72 with a higher score indicating more severe disease. Change from baseline based on a mixed-effects model for repeated measures with a positive change indicating a worsening of symptoms.
| Units on a scale | Placebo-controlled Phase - Placebo | Placebo-controlled Phase - Apremilast 30 mg BID |
|---|---|---|
| Change From Baseline in PPPASI Total Score at Week 16 | -11.03 ± 1.260 | -16.48 ± 1.224 |
The AUC for PPSI total score from baseline through Week 16 is the sum of the AUCs in each time interval specified by the dates of the visits and is calculated based on the linear trapezoidal method. PPSI is a disease-specific assessment tool for grading the severity of PPP lesions. Evaluation of skin lesion sites are assessed separately for erythema, pustules/vesicle and desquamation/scale, which are each rated on a scale of 0 to 4. The PPSI produces a total numeric score that ranges from 0 to 12. A higher score indicates more severe disease.
| Scores * Day | Placebo-controlled Phase - Placebo | Placebo-controlled Phase - Apremilast 30 mg BID |
|---|---|---|
| AUC for PPSI Total Score From Baseline Through Week 16 | 725.62 (668.09 to 783.15) | 564.63 (507.35 to 621.90) |
PPSI is a disease-specific assessment tool for grading the severity of PPP lesions. Evaluation of skin lesion sites are assessed separately for erythema, pustules/vesicle and desquamation/scale, which are each rated on a scale of 0 to 4. The PPSI produces a total numeric score that ranges from 0 to 12. A higher score indicates more severe disease. A positive change from baseline indicates a worsening of symptoms.
| Percent Change | Placebo-controlled Phase - Placebo | Placebo-controlled Phase - Apremilast 30 mg BID |
|---|---|---|
| Week 2 | -6.25 ± 19.409 | -24.70 ± 19.780 |
| Week 4 | -13.84 ± 25.629 | -34.58 ± 23.190 |
| Week 6 | -20.02 ± 20.639 | -40.50 ± 23.035 |
| Week 8 | -30.12 ± 29.340 | -40.76 ± 23.019 |
| Week 10 | -27.42 ± 29.635 | -44.22 ± 24.890 |
| Week 12 | -31.18 ± 27.817 | -46.47 ± 25.202 |
| Week 14 | -34.98 ± 28.205 | -50.16 ± 25.488 |
| Week 16 | -30.90 ± 25.414 | -48.96 ± 21.821 |
PPSI is a disease-specific assessment tool for grading the severity of PPP lesions. Evaluation of skin lesion sites are assessed separately for erythema, pustules/vesicle and desquamation/scale, which are each rated on a scale of 0 to 4. The PPSI produces a total numeric score that ranges from 0 to 12. A higher score indicates more severe disease. Change from baseline based on a mixed-effects model for repeated measures with a positive change indicating a worsening of symptoms.
| Units on a scale | Placebo-controlled Phase - Placebo | Placebo-controlled Phase - Apremilast 30 mg BID |
|---|---|---|
| Change From Baseline in PPSI Total Score at Week 16 | -2.56 ± 0.303 | -4.19 ± 0.293 |
The PGA for palms and soles was used to determine the participants PPP lesions on palms and soles. Lesions on palms and soles were graded based on the following scales: 0 = Clear 1. = Almost clear/Minimal 2. = Mild 3. = Moderate 4. = Severe 5. = Very severe. The percentage of of participants with a post baseline score of 0 or 1 (responders) are reported. Missing values at were imputed using NRI as the primary method, by which a participant without sufficient data for the response determination was considered a non-responder.
| Percentage of Participants | Placebo-controlled Phase - Placebo | Placebo-controlled Phase - Apremilast 30 mg BID |
|---|---|---|
| Week 2 | 0.0 | 2.2 |
| Week 4 | 2.3 | 4.3 |
| Week 6 | 2.3 | 4.3 |
| Week 8 | 9.1 | 8.7 |
| Week 10 | 9.1 | 13.0 |
| Week 12 | 9.1 | 15.2 |
| Week 14 | 9.1 | 17.4 |
| Week 16 | 4.5 | 19.6 |
The PGA for palms and soles was used to determine the participants PPP lesions on palms and soles. Lesions on palms and soles were graded based on the following scales: 0 = Clear 1. = Almost clear/Minimal 2. = Mild 3. = Moderate 4. = Severe 5. = Very severe. The percentage of of participants with at least a 2 grade improvement from baseline (stringent responders) are reported. issing values at were imputed using NRI as the primary method, by which a participant without sufficient data for the response determination was considered a non-responder.
| Percentage of Participants | Placebo-controlled Phase - Placebo | Placebo-controlled Phase - Apremilast 30 mg BID |
|---|---|---|
| Week 2 | 0.0 | 2.2 |
| Week 4 | 2.3 | 4.3 |
| Week 6 | 2.3 | 4.3 |
| Week 8 | 9.1 | 6.5 |
| Week 10 | 9.1 | 10.9 |
| Week 12 | 9.1 | 15.2 |
| Week 14 | 9.1 | 17.4 |
| Week 16 | 4.5 | 17.4 |
Participants assessed the degree of both pruritus itching and skin discomfort/pain as symptoms on hands and feet caused by PPP on a VAS. Each score ranged from 0 to 100. The left-hand boundary (0) on the VAS represents no itch/pain and the right-hand boundary (100) represents itch/pain as severe as can be imagined by participant.
| Units on scale | Placebo-controlled Phase - Placebo | Placebo-controlled Phase - Apremilast 30 mg BID |
|---|---|---|
| Itching Week 2 | -2.4 ± 25.07 | -25.0 ± 24.42 |
| Itching Week 4 | -7.9 ± 21.39 | -22.7 ± 26.36 |
| Itching Week 6 | -9.3 ± 29.65 | -22.4 ± 29.37 |
| Itching Week 8 | -19.0 ± 25.53 | -24.8 ± 29.38 |
| Itching Week 12 | -14.9 ± 35.82 | -28.3 ± 28.55 |
| Itching Week 16 | -10.5 ± 30.81 | -26.8 ± 28.65 |
| Discomfort/Pain Week 2 | -0.7 ± 32.47 | -20.2 ± 26.73 |
| Discomfort/Pain Week 4 | -6.9 ± 30.39 | -21.6 ± 29.21 |
| Discomfort/Pain Week 6 | -6.7 ± 28.80 | -22.4 ± 33.16 |
| Discomfort/Pain Week 8 | -15.5 ± 31.14 | -22.0 ± 29.02 |
| Discomfort/Pain Week 12 | -14.1 ± 32.07 | -27.6 ± 28.14 |
| Discomfort/Pain Week 16 | -13.5 ± 27.51 | -25.3 ± 29.51 |
Collected over Placebo-controlled Phase: Week 0 to Week 16. Active-treatment Phase: After Week 16 to Week 32.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo-controlled Phase - Placebo | 0/44 (0%) | 0/44 (0%) | 16/44 (36.4%) |
| Placebo-controlled Phase - Apremilast 30 mg BID | 0/46 (0%) | 0/46 (0%) | 32/46 (69.6%) |
| Active-treatment Phase - Apremilast 30 mg BID | 0/87 (0%) | 3/87 (3.4%) | 40/87 (46%) |
| Event | Placebo-controlled Phase - Placebo | Placebo-controlled Phase - Apremilast 30 mg BID | Active-treatment Phase - Apremilast 30 mg BID |
|---|---|---|---|
| ConstipationGastrointestinal disorders | 0/44 | 0/46 | 1/87 |
| VolvulusGastrointestinal disorders | 0/44 | 0/46 | 1/87 |
| COVID-19 pneumoniaInfections and infestations | 0/44 | 0/46 | 1/87 |
| PeritonitisInfections and infestations | 0/44 | 0/46 | 1/87 |
| Event | Placebo-controlled Phase - Placebo | Placebo-controlled Phase - Apremilast 30 mg BID | Active-treatment Phase - Apremilast 30 mg BID |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 6/44 | 12/46 | 8/87 |
| Abdominal discomfortGastrointestinal disorders | 1/44 | 7/46 | 6/87 |
| NauseaGastrointestinal disorders | 2/44 | 6/46 | 3/87 |
| HeadacheNervous system disorders | 0/44 | 6/46 | 4/87 |
| EczemaSkin and subcutaneous tissue disorders | 5/44 | 3/46 | 3/87 |
| Faeces softGastrointestinal disorders | 2/44 | 5/46 | 3/87 |
| NasopharyngitisInfections and infestations | 2/44 | 5/46 | 5/87 |
| Dermatitis contactSkin and subcutaneous tissue disorders | 1/44 | 5/46 | 5/87 |
| Palmoplantar pustulosisSkin and subcutaneous tissue disorders | 1/44 | 0/46 | 8/87 |
| FolliculitisInfections and infestations | 4/44 | 1/46 | 3/87 |
| Age, Continuous(years) | Placebo Then Apremilast 30mg BID | Apremilast 30 mg BID Then Apremilast 30 mg BID | Total |
|---|---|---|---|
| Mean | 54.7 ± 11.68 | 54.9 ± 11.30 | 54.8 ± 11.42 |
| Sex: Female, Male(Participants) | Placebo Then Apremilast 30mg BID | Apremilast 30 mg BID Then Apremilast 30 mg BID | Total |
|---|---|---|---|
| Female | 33 | 36 | 69 |
| Male | 11 | 10 | 21 |
| Ethnicity (NIH/OMB)(Participants) | Placebo Then Apremilast 30mg BID | Apremilast 30 mg BID Then Apremilast 30 mg BID | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 44 | 46 | 90 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo Then Apremilast 30mg BID | Apremilast 30 mg BID Then Apremilast 30 mg BID | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 44 | 46 | 90 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Palmo-plantar Pustulosis Area and Severity Index (PPPASI) Score(Score on a scale) | Placebo Then Apremilast 30mg BID | Apremilast 30 mg BID Then Apremilast 30 mg BID | Total |
|---|---|---|---|
| Mean | 24.93 ± 8.915 | 25.03 ± 8.675 | 24.98 ± 8.744 |
| Palmo-plantar Severity Index (PPSI) Total Score(Score on a Scale) | Placebo Then Apremilast 30mg BID | Apremilast 30 mg BID Then Apremilast 30 mg BID | Total |
|---|---|---|---|
| Mean | 8.2 ± 1.49 | 8.3 ± 1.48 | 8.20 ± 1.48 |
| Physician's Global Assessment (PGA) Score for Palms and Soles(Participants) | Placebo Then Apremilast 30mg BID | Apremilast 30 mg BID Then Apremilast 30 mg BID | Total |
|---|---|---|---|
| 0 = Clear | 0 | 0 | 0 |
| 1 = Almost clear/Minimal | 0 | 0 | 0 |
| 2 = Mild | 1 | 3 | 4 |
| 3 = Moderate | 24 | 16 | 40 |
| 4 = Severe | 17 | 21 | 38 |
| 5 = Very severe | 2 | 6 | 8 |
| Participants Visual Analogue Scale (VAS) Assessment for PPP Symptoms(Score on a Scale) | Placebo Then Apremilast 30mg BID | Apremilast 30 mg BID Then Apremilast 30 mg BID | Total |
|---|---|---|---|
| Itching | 57.0 ± 27.8 | 50.3 ± 31.58 | 53.5 ± 29.85 |
| Discomfort/Pain | 50.3 ± 29.98 | 45.4 ± 31.92 | 47.8 ± 30.93 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
Data sharing details ↗ · www.amgen.com
Ran from Oct 2019 to primary completion in Jan 2021, 15 months.
Results were first posted in Jan 2022, 11 months after primary completion.
Of 146 industry-sponsored phase 2 interventional studies under Psoriasis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's 15 months is above that.
Counting every sponsor, half of 175 studies reached it within 14 months; a quarter within 9 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Apremilast